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Summary
 
We investigated the role of Bruton’s tyrosine kinase (Btk) in Fc
 
e
 
RI-dependent activation of
mouse mast cells, using 
 
xid
 
 and 
 
btk null
 
 mutant mice. Unlike B cell development, mast cell de-
velopment is apparently normal in these 
 
btk
 
 mutant mice. However, mast cells derived from
these mice exhibited significant abnormalities in Fc
 
e
 
RI-dependent function. 
 
xid
 
 mice primed
with anti-dinitrophenyl monoclonal IgE antibody exhibited mildly diminished early-phase and
severely blunted late-phase anaphylactic reactions in response to antigen challenge in vivo.
Consistent with this finding, cultured mast cells derived from the bone marrow cells of 
 
xid
 
 or
 
btk null
 
 mice exhibited mild impairments in degranulation, and more profound defects in the
production of several cytokines, upon Fc
 
e
 
RI cross-linking. Moreover, the transcriptional ac-
tivities of these cytokine genes were severely reduced in Fc
 
e
 
RI-stimulated 
 
btk
 
 mutant mast
cells. The specificity of these effects of 
 
btk
 
 mutations was confirmed by the improvement in the
ability of 
 
btk
 
 mutant mast cells to degranulate and to secrete cytokines after the retroviral trans-
fer of wild-type 
 
btk
 
 cDNA, but not of vector or kinase-dead 
 
btk
 
 cDNA. Retroviral transfer of
Emt (
 
5 
 
Itk/Tsk), Btk’s closest relative, also partially improved the ability of 
 
btk
 
 mutant mast
cells to secrete mediators. Taken together, these results demonstrate an important role for Btk
in the full expression of Fc
 
e
 
RI signal transduction in mast cells.
 
M
 
ast cells and basophils play pivotal roles in the initia-
tion of allergic reactions. Cross-linking of the high-
affinity receptor for IgE (Fc
 
e
 
RI) on these cells activates in-
tracellular signaling pathways that lead to degranulation and
release of histamine and other preformed mediators, de
novo synthesis and release of lipid mediators, and secretion
of preformed and de novo synthesized cytokines (1, 2).
These bioactive mediators are thought to lead to allergic
inflammation.
Fc
 
e
 
RI consists of one molecule of an 
 
a
 
 subunit that is
capable of binding to IgE, one molecule of a 
 
b
 
 subunit
with four transmembrane segments, and two molecules of
disulfide-bonded 
 
g
 
 subunits (3). None of these subunits
have discernible enzyme structures, but both the 
 
b
 
 and 
 
g
 
subunits have the immunoreceptor tyrosine-based activa-
tion motif (ITAM; references 4, 5).
 
1
 
 After Fc
 
e
 
RI cross-
linking, tyrosine phosphorylation of several intracellular
proteins is the earliest recognizable activation event (6).
The importance of protein tyrosine kinases (PTKs) in
Fc
 
e
 
RI-mediated mediator secretion has been demonstrated
 
1
 
Abbreviations used in this paper:
 
 BMMC, bone marrow–derived cultured
mast cells; Btk, Bruton’s tyrosine kinase; ITAM, immunoreceptor ty-
rosine–based activation motif; NFAT, nuclear factor of activated T cells;
PCA, passive cutaneous anaphylactic; PH, pleckstrin homology; PKC,
protein kinase C; PLC, phospholipase C; PTK, protein tyrosine kinase;
SCF, stem cell factor; SH, Src homology.
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Btk Functions in Mast Cells
 
by showing that treatment with a variety of PTK inhibitors
can abrogate Fc
 
e
 
RI-dependent activation of mast cells (7,
8). Two specific PTKs, Lyn and Syk, that belong to the Src
and Syk/ZAP families, respectively, were shown to be es-
sential for Fc
 
e
 
RI-mediated mast cell activation (9–11). Ac-
cording to a generally accepted hypothesis (12), Lyn that is
associated with the 
 
b
 
 subunit in unstimulated cells is acti-
vated upon Fc
 
e
 
RI cross-linking. Subsequently, activated
Lyn phosphorylates tyrosine residues within the ITAM se-
quences in the 
 
b
 
 and 
 
g
 
 subunits. Phosphorylated ITAM
(phospho-ITAM) in the 
 
b
 
 subunit recruits new molecules
of Lyn through the Src homology 2 (SH2) domain–phos-
photyrosine interaction while phospho-ITAM in the 
 
g
 
subunit recruits Syk by the same mechanism (13). Lyn and
Syk are activated when bound to phospho-ITAMs (14,
15), and such activated Lyn and Syk in turn phosphorylate
downstream targets such as phospholipase C (PLC)–
 
g
 
.
Three Tec family PTKs, Btk, Emt/Itk/Tsk (Emt), and
Tec, are also expressed in mast cells (16, 17). Among them,
Btk and Emt are activated upon Fc
 
e
 
RI cross-linking, sug-
gesting a functional role in mast cell activation (18, 19).
However, in contrast with Lyn and Syk (20–22), these
PTKs do not appear to be receptor-associated molecules.
Moreover, both Btk and Emt have important roles that are
apparently unrelated to their involvement in Fc
 
e
 
RI-depen-
dent mast cell activation. Thus, Btk plays an essential role
in the differentiation and activation of B lymphocytes: de-
fects in the 
 
btk 
 
gene lead to X-linked agammaglobulinemia
in humans (23, 24) and X-linked immunodeficiency (
 
xid
 
)
in mice (25, 26). In addition, subsequent studies have im-
plicated Btk in a number of signal transduction pathways in
immune cells, including those for the B cell antigen recep-
tor (27–29), CD38 (30, 31), CD40 (32), IL-5 (33), IL-6
(34), and IL-10 (35). Emt is considered a “T cell equiva-
lent” of Btk, and is involved in T cell development and
early activation events triggered through TCR/CD3 and
CD28 (36–38).
Both 
 
xid
 
 (a mutation which results in the substitution of
Arg with Cys at residue 28 in the Btk protein) and 
 
btk null
 
mice exhibit essentially the same phenotype: these muta-
tions lead to reduced numbers of mature conventional B
cells, a severe deficiency of B1 B cells, a deficiency of se-
rum IgM and IgG3, and defective responses to various B
cell activators in vitro and to immunization with thymus-
independent type II antigens in vivo (39, 40).
In this study, we analyzed Btk functions in mast cells in
vivo and in vitro. Although 
 
btk
 
 mutant mast cells appear
normal in many aspects of development in vitro or in vivo,
they exhibited multiple abnormalities in Fc
 
e
 
RI-mediated
functions. 
 
Btk
 
 mutant mast cells exhibited mild to moder-
ate impairment of Fc
 
e
 
RI-mediated degranulation and his-
tamine release, and more severe impairment of Fc
 
e
 
RI-
mediated cytokine production in vitro. 
 
Btk 
 
mutant mice
exhibited correspondingly mild versus severe abnormalities
in the early versus late phases of Fc
 
e
 
RI-mediated cutaneous
inflammatory responses in vivo. Furthermore, we found
that both 
 
xid
 
 and 
 
null
 
 mutations of the 
 
btk
 
 gene result in
defects in the transcriptional regulation of cytokine genes
in mast cells stimulated via Fc
 
e
 
RI, and such defects in 
 
btk
 
mutant mast cells could be improved by retroviral gene
transfer of wild-type (wt) 
 
btk
 
 cDNA. These results collec-
tively demonstrate the involvement of Btk in the full ex-
pression of Fc
 
e
 
RI signal transduction.
 
Materials and Methods
 
Passive Cutaneous Anaphylactic (PCA) Reactions.
 
In homolo-
gous PCA experiments, 10 
 
m
 
l of various amounts of anti-DNP
monoclonal IgE was intradermally injected into the ear of mice.
24 h later, 0.25 ml saline solution containing 1 mg/ml DNP con-
jugates of BSA (DNP
 
8.7
 
-BSA) and 0.5% Evans blue dye was intra-
venously injected. The amounts of extravasated dye were mea-
sured after 30 min by extracting ears with potassium hydroxide as
previously described (41). In another type of experiment, CBA/J
and CBA/CaHN-
 
xid
 
/J mice received 1.0 ml anti-DNP mono-
clonal IgE antibody intravenously. 24 h later, a skin reaction was
elicited by applying 10 
 
m
 
l 0.75% dinitrofluorobenzene acetone–
olive oil solution to both sides of the ears. The reaction was as-
sessed by measuring the ear thickness using an engineer’s mi-
crometer, Upright Dial Gauge (Peacock, Tokyo, Japan), at the
indicated times after antigen challenge (42).
 
Cell Culture and Stimulation.
 
Bone marrow cells taken from
mouse femurs were incubated in the presence of IL-3 as previ-
ously described (7). After 4 wk of culture, cells (
 
.
 
95% mast cells,
termed BMMCs for bone marrow–derived cultured mast cells)
were incubated overnight with anti-DNP IgE antibody. Unless
otherwise indicated (e.g., in cells stimulated for release of hista-
mine or leukotrienes, see below), sensitized cells were stimulated
for 24 h with 30 ng/ml DNP conjugates of human serum albu-
min (DNP-HSA) in RPMI 1640 medium supplemented with
10% fetal bovine serum, 50 
 
m
 
M 2-ME, 2 mM glutamine, and IL-3.
For most retroviral transfection experiments, bone marrow cells
cultured in the presence of IL-3 for 2–3 wk were expanded in the
presence of both IL-3 and recombinant rat stem cell factor (SCF;
gift of Kirin Brewery Co., Tokyo, Japan) for another 1–2 wk. At
this point, 
 
.
 
95% of the cells were mast cells, termed sBMMCs
(for SCF-maintained BMMCs).
 
Northern Blot Analysis.
 
Total cellular RNAs were isolated us-
ing RNAzol B (Tel-Test, Inc., Friendswood, TX) according to
the manufacturer’s instructions. RNAs fractionated by formalde-
hyde/agarose gel electrophoresis were blotted onto nitrocellulose
membranes. Mouse TNF-
 
a
 
 (obtained from the American Type
Culture Collection, Rockville, MD) and c-
 
myc
 
 (a gift from D.R.
Green, La Jolla Institute for Allergy and Immunology, La Jolla,
CA) cDNA fragments were gel-purified and 
 
32
 
P-labeled with a
Megaprime DNA labeling kit (Pharmacia Biotech, Piscataway,
NJ). Membranes were hybridized with 
 
32
 
P-labeled probe purified
through Elutip-d (Schleicher & Schuell, Keene, NH). Hybridized
bands were detected by autoradiography.
 
Immunoblot Analysis.
 
Immunologically stimulated cells were
lysed in 1% NP-40–containing buffer. Cleared lysates were di-
rectly analyzed by SDS-PAGE or immunoprecipitated with poly-
clonal anti–TNF-
 
a antibodies (Genzyme Corp., Cambridge, MA)
before SDS-PAGE. Proteins in gels were electrophoretically
transferred to Immobilon-P membranes (Millipore Corp., Bed-
ford, MA). Membranes were blocked, incubated with anti–TNF-a,
anti-Btk (43), anti-Emt (44), or other appropriate primary anti-
bodies, and then with horseradish peroxidase–conjugated second-
ary antibody. Immunoreactive bands were detected by an enhanced
chemiluminescence kit (Amersham Corp., Arlington Heights, IL).
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Transfection. Murine btk cDNA in pME18S vector (16) was
used for in vitro mutagenesis using two-step PCR procedures
(45) to generate K430R and other btk mutants. The wt and mu-
tant btk cDNAs confirmed by sequencing were inserted into the
Moloney murine leukemia virus–based retroviral vectors, pMX-
neo or pMX-puro (46). Retroviruses were generated by transient
transfection of BOSC-23 packaging cells (47) with Lipofectamine
(GIBCO BRL, Gaithersburg, MD). BMMCs or sBMMCs de-
rived from male xid or btk null mice were infected with these ret-
roviruses in the presence of 10 mg/ml polybrene. Selection with
G418 (for xid-BMMCs and xid-sBMMCs) or puromycin (for btk
null–BMMCs and btk null–sBMMCs) was started 48 h after infec-
tion. Mass populations of G418- or puromycin-resistant cells
were grown and then cultured in the absence of selection drug
for 48 h before immunological stimulation.
Measurements of Secreted Histamine, Cytokines, and Leukotrienes.
Histamine released into the media during a 45-min stimulation
was measured by an automatic fluorometric assay (48). Concen-
trations of antigen (ED50) for half maximal histamine release was
estimated using 77% (wt) and 79% (xid) as maximal responses.
TNF-a, IL-2, IL-4, IL-6, and GM-CSF secreted into the media
for 24 h were measured by ELISA kits (Endogen, Woburn, MA).
Leukotrienes secreted into media for 30 min were analyzed by an
enzyme immunoassay kit for leukotriene C4/D4/E4 (Amersham
Corp.).
Transcriptional Activity Assay with Luciferase Reporter Constructs.
Luciferase reporter constructs, mouse IL-2 (2321), nuclear factor
of activated T cells (NFAT)d–luc, NFkB–luc, and c-fos–luc have
been previously described (49, 50). To engineer the human
TNF-a (2200)–luc, PCR was done to amplify a DNA fragment
containing the TNF-a promoter region (2199 to 168). This
PCR fragment was inserted into the SmaI/BglII site of pGL3-
Basic vector (Promega Corp., Madison, WI). 1.0–1.5 3 107 mast
cells were transfected with 5–10 mg reporter plasmids by elec-
troporation at 400 V, 950 mF using a Gene Pulser II apparatus
(Bio-Rad, Hercules, CA). Transfected cells were sensitized with
anti-DNP monoclonal IgE antibody overnight, and left unstimu-
lated or stimulated with 30 ng/ml DNP-HSA for 8 h before cell
harvest. Cells were lysed in 0.2% Triton X-100 in 100 mM po-
tassium phosphate buffer (pH 7.8)/1 mM dithiothreitol. Lumi-
nescence of cleared lysates was measured after addition of lu-
ciferin solution using a luminometer (Monolight 2010; Analytical
Luminescence Laboratory, San Diego, CA).
Quantitation of Tissue Mast Cells. Tissue mast cells in ear skin
were quantified by light microscopy at 3400 by an observer who
was unaware of the identity (i.e., mouse genotype) of the individ-
ual specimens, in 1-mm, Epon-embedded, Giemsa-stained sec-
tions, as previously described (51). Results were expressed as mast
cells (mean 6 SEM) per mm2 of dermis (51).
Results
Mast Cell Development Is Not Affected by btk Mutations.
First, we assessed the effects of btk null and xid mutations on
several aspects of mast cell development and phenotype in
vivo or in vitro. Mast cells in wt and btk null mouse ear
skins were similar in their morphology and anatomical dis-
tribution (data not shown) and numbers: 125 6 27.9/mm2
of dermis (129/C57BL F2) versus 123 6 32.2/mm2 of der-
mis (btk null). The phenotypes of BMMCs were indistin-
guishable between wt (CBA/J) and xid (CBA/HCaN-xid/J)
as well as between wt (129/C57BL F2) and btk null mice in
their morphology when the cells were stained with May-
Giemsa or with Alcian Blue (data not shown), and in num-
bers of IgE binding sites: (4.6 6 1.2) 3 104/cell (CBA/J)
versus (3.7 6 2.0) 3 104/cell (CBA/HCaN-xid/J); (7.9 6
2.4) 3 104/cell (129/C57BL F2) versus (8.2 6 2.9) 3 104/
cell (btk null). The wt- and btk null–BMMCs were similar in
the expression of various signaling proteins, including
FceRI b and g subunits, Lyn, Syk, Grb2, Shc, Sos, H-Ras,
PLC-g1, SPY75 (5 HS1), protein kinase C (PKC; a, bI,
bII, d, e, h, u, and z isoforms), ERK1/2, JNK1/2, p38,
PAK65, SEK1, and c-Jun (data not shown). Therefore, we
concluded that either btk null or xid mutations apparently
do not significantly interfere multiple aspects of mast cell
development in vivo and in vitro.
Effects of btk Mutations on Anaphylactic Reactions In Vivo.
We next tested the effects of the btk mutations on mast cell
activation events induced by FceRI cross-linking. Two
types of PCA experiments were carried out. Mice primed
by intradermal injection of anti-DNP IgE for 24 h were in-
jected intravenously with antigen and Evans blue dye. Ex-
travasation of Evans blue dye, due to increased blood vessel
permeability as a result of PCA reactions, was quantified.
The extravasation of Evans blue dye during the first 30 min
of the PCA reactions, which is dependent mainly on hista-
mine and serotonin released from activated mast cells (52),
was slightly but significantly reduced at all the tested IgE
doses in xid mice compared with wt mice (Fig. 1 A). To
examine another type of PCA reaction (42), mice were
sensitized with anti-DNP IgE 24 h before a solution of
0.75% dinitrofluorobenzene (hapten) was applied epicuta-
neously to the ear skin. xid mice exhibited little or no IgE/
antigen-specific edema, whereas wt mice exhibited a prom-
inent response that was detectable 4 h or later after antigen
stimulation (Fig. 1 B). This late reaction is known to be at
least partly due to TNF-a secreted from activated mast cells
(51). Indeed, injection into the PCA-inducing site of wt
mice with a neutralizing antibody to TNF-a just before
antigen application significantly suppressed the develop-
ment of the edema associated with the late phase of the re-
action, as measured 24 h after antigen stimulation (Fig. 1 C).
Significant defects in both the early and late phases of PCA
reactions were also observed in btk null mice (data not
shown).
Effects of btk Mutations on FceRI-mediated Degranulation and
Cytokine Secretion. To investigate the cellular basis for the
diminished PCA reactions in btk mutant mice, the capaci-
ties to degranulate and release histamine and to produce
and secrete cytokines were compared between BMMCs
derived from the wt mice and the xid (or btk null) mice.
Consistent with the modest defect in the early phase of
PCA reactions and the more striking defect in the later
phase, xid-BMMCs showed relatively mild defects in
FceRI-elicited histamine release but more severe impair-
ments in cytokine secretion compared with wt-BMMCs.
Maximal histamine responses (70–80% of the cellular con-
tent) were similar between wt- and xid-BMMCs. However,
xid-BMMCs exhibited a marked reduction in histamine re-
lease at suboptimal doses of antigen, and the sensitivity of
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xid-BMMCs to antigen stimulation was reduced by 3.8-
fold compared with wt-BMMCs (ED50 5 4.4 ng/ml [wt]
versus 17 ng/ml [xid], see Fig. 2 A). Btk null–BMMCs ex-
hibited a somewhat more severe defect with a reduction in
maximal histamine release in addition to reduced antigen
sensitivity (Fig. 2 B).
In contrast to the relatively mild defect in histamine re-
lease, the differences in TNF-a secretion between the xid-
and wt-BMMCs stimulated with an optimal concentration
(30 ng/ml) of antigen ranged between 1:3.2 and 1:12 (a
mean of 1:6.7, n 5 5, see Fig. 2 C). FceRI-stimulated se-
cretion of IL-2, IL-6, and GM-CSF was also impaired to a
similar extent in xid-BMMCs (Fig. 2 C and data not
shown). Similarly reduced cytokine responses were ob-
served in btk null cells (data not shown). Wt-, xid-, and btk
null–BMMCs secreted barely detectable amounts (,40
pg/ml) of IL-4 in response to an immunologic stimulation
through FceRI (data not shown). These results suggest that
the abnormalities in the expression of PCA reactions in xid
and btk null mice reflect the mildly reduced degranulation
and markedly defective cytokine secretion exhibited by btk
mutant mast cells upon FceRI cross-linking.
Defects in the Transcription of Cytokine Genes in btk Mutant
Mast Cells. To further characterize the defects in TNF-a
production and secretion in xid-BMMCs, we analyzed lev-
els of TNF-a mRNA and protein in xid- and correspond-
ing wt-BMMCs. As revealed by Northern blotting (Fig.
3 A), in wt-BMMCs, TNF-a mRNA was almost unde-
tectable before stimulation but increased dramatically
within 1 h after FceRI cross-linking and decreased within
the next few hours. However, under the same conditions
of stimulation, xid-BMMCs produced less than one fifth
the amount of TNF-a mRNA at its peak.
The membrane-bound TNF-a precursor (53), which
was barely detectable before stimulation, increased after
FceRI cross-linking and reached a plateau level by 2–3 h
after stimulation in wt-BMMCs (Fig. 3 B and data not
shown). However, stimulation of xid-BMMCs led to only
a slight increase in membrane-bound TNF-a content. Cel-
lular pulse and chase experiments with [35S]methionine
showed that there was no significant difference in the intra-
Figure 1. PCA reactions in CBA/J (wt) and CBA/CaHN-xid/J (xid) mice. (A) Mice were left unsensitized [PCA(-)] or sensitized by intradermal injec-
tion of the indicated amounts of anti-DNP IgE in 10 ml solution at the ear 24 h before antigen challenge. Mice were stimulated by intravenous injection
of DNP8.7-BSA and Evans blue dye for 30 min, and then the amount of extravasated Evans blue dye in the IgE-injected and control ears was measured as
previously described (41). Statistical significance is indicated by ** (P ,0.01) and *** (P ,0.001). (B) Mice were left unsensitized or sensitized by intrave-
nous injection of anti-DNP monoclonal IgE 24 h before antigen challenge. 25 ml of 0.75% dinitrofluorobenzene was applied on both sides of the ear, and
the ear thickness was measured (42) at the indicated intervals. In C, anti–TNF-a antibody (aTNF, 80,000 U/0.2 ml/mouse) or normal rabbit serum
(NRS, 0.2 ml/mouse) was intravenously injected just before antigen challenge in wt mice which had been sensitized with IgE and challenged with anti-
gen (hapten) epicutaneously as in B; ear thickness was measured 24 h after antigen challenge.
Figure 2. FceRI-induced histamine release and cytokine secretion
from wt and xid-BMMCs. BMMCs were sensitized by overnight incuba-
tion with 1 mg/ml anti-DNP monoclonal IgE antibody. Cells resus-
pended in Tyrode solution (A and B) or culture media (C) were stimu-
lated by the indicated concentrations of DNP-HSA for 45 min (A and B)
or 24 h (C). Histamine released into the buffer was measured by an auto-
matic fluorometric assay (A and B). Cytokines secreted into the culture
media during 24 h were measured by ELISA (C). The results of histamine
release are mean values of duplicates per point, with SEM ,5% of the
mean. The results shown in A for xid-BMMCs and their corresponding
wt-BMMCs are representative of those obtained in more than five exper-
iments. The results shown in B are representative of those from two ex-
periments. Cytokine measurements shown in C were performed in tripli-
cate and mean values are shown, with SEM ,10% of the mean. The
results in C are representative of those from at least seven experiments.
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cellular stability of TNF-a protein between wt- and xid-
BMMCs (data not shown).
Taken together, these data suggest that Btk regulates
TNF-a production at the transcriptional level. To test this
possibility directly, we transfected BMMCs with luciferase
reporter constructs under the control of TNF-a or IL-2
promoters. Transcription of both the TNF-a and IL-2 re-
porter constructs was strongly induced when wt-BMMCs
were stimulated by FceRI cross-linking. In btk null–BMMCs,
the induced transcriptional activity of the TNF-a (2200)–
luc construct was z50% of that in wt-BMMCs (Fig. 4 A).
Induction of transcriptional activities of the IL-2 (2321)–
luc construct was 4–5-fold less in btk null–BMMCs com-
pared with its activity in wt cells (Fig. 4 A). Similar results
were obtained when the transcriptional activity of the
TNF-a and IL-2 constructs was assessed in xid- versus wt-
BMMCs (data not shown). We then performed additional
experiments to assess the specificity of the transcriptional
regulation of cytokine genes by Btk. We found that btk
null–sBMMCs that had been stably transfected with wt btk
exhibited higher transcriptional activities of the IL-2
(2321)–luc, TNF-a (2200)–luc, and NFAT–luc con-
structs than the cells transfected with vector or kinase-dead
(K430R) btk (Fig. 4 B). By contrast, all three cell popula-
tions exhibited similar low levels of activity for the NFkB
and c-fos constructs (Fig. 4 B).
The NFAT family of transcription factors and AP-1 pro-
teins play essential roles in the expression of the IL-2 (54,
55) and TNF-a genes (56–58). These results indicate that
defects in the production/secretion of cytokines upon
FceRI cross-linking in btk mutant mast cells are due, at
least in part, to the inefficient transcription of these genes
and may involve the signal transduction pathways leading
to the activation of NFAT and/or AP-1 (Jun–Fos or Jun–
Jun dimers). This notion is consistent with our recent data
that Btk regulates JNK, an activator of c-Jun (59).
Gene Transfer–mediated Enhancement of the Ability of btk
Mutant Mast Cells to Secrete Cytokines and Degranulate. To fur-
ther investigate the relationship between btk mutations and
impairment of mast cell functions, we measured cytokine
production in btk mutant mast cells that had been reconsti-
tuted with Btk by stable or transient transfection. For most
of these experiments, we used mast cells (sBMMCs) that
had been expanded in the presence of both IL-3 and SCF.
When xid-sBMMCs that had been transfected with wt btk
cDNA were stimulated by FceRI cross-linking, we ob-
served a substantial enhancement of TNF-a–producing/
secretory ability as compared to that seen in xid-sBMMCs
that had been transfected with neo vector alone, with xid or
kinase-dead (K430R) mutant btk cDNAs, or with wt syk or
wt lyn cDNAs (Fig. 5 A). Expression of the transfected
genes at comparable levels was confirmed by increased im-
munoreactive Btk proteins in wt, xid, and K430R mutant
btk–transfected cells (Fig. 5 D, left). Transfectants expressing
the constitutively active Btk* protein with the E41K substi-
Figure 4. Transcriptional activity of luciferase reporter constructs in wt
mast cells or btk null mast cells reconstituted with wt or K430R btk cDNAs.
Promoter reporter constructs, IL-2 (2321)–luc, TNF-a (2200)–luc,
NFAT–luc, NFkB–luc, or c-fos–luc, were transfected into wt or btk null
mast cells (A) or btk null mast cells reconstituted with vector, wt btk, or
K430R btk retroviruses (B). Luciferase activity was measured in cell ly-
sates that were prepared 8 h after antigen stimulation or mock stimulation.
Fold activities in FceRI-stimulated cells versus unstimulated cells (5 1)
are shown. The results shown are representative of those obtained in at
least three experiments of each type.
Figure 3. Analysis of TNF-a mRNA and protein in wt and xid mast
cells. (A) Northern blot analysis for TNF-a mRNA of total cellular
RNAs from immunologically stimulated BMMCs (top). The same blot
was reprobed with c-myc cDNA (bottom). FceRI cross-linking did not
change c-myc mRNA levels. Because the blot was not stripped before
reprobing, the TNF-a mRNA signals were also detected by the second
probing. (B) Immunoblotting analysis of membrane-bound TNF-a (pro-
TNFa) in wt- and xid-BMMCs. Cells were immunologically stimulated
via FceRI for the indicated times. Detergent lysates were analyzed by
Western blotting with polyclonal anti–TNF-a antibodies. Positions of
molecular mass standards (in kilodaltons) and pro–TNF-a are indicated
on the left and right, respectively. 
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Figure 5. Effects of retroviral transfection of btk cDNAs on the ability of xid or btk null mast cells to produce cytokines or degranulate. (A) xid-sBM-
MCs were infected with the retroviruses encoding wt, kinase-dead (K430R), xid, or E41K mutant btk cDNAs. As controls, xid-sBMMCs were also trans-
fected with lyn or syk cDNAs. G418-resistant cells were immunologically stimulated via the FceRI and the TNF-a secreted during the next 24 h was
measured. Levels of TNF-a secreted over 24 h by FceRI-activated, but nontransfected xid-BMMCs, xid-sBMMCs, wt-BMMCs, and wt-sBMMCs, are
also shown. The results presented are representative of those obtained in three separate experiments. The TNF-a values of duplicate measurements varied
,10%. (B) FceRI-induced secretion of TNF-a, IL-2, IL-6, and GM-CSF from btk null–sBMMCs transfected with wt, K430R, xid (R28C), SH2
(R307K), or SH3 (P265L) mutant btk cDNAs; also shown is cytokine secretion from vector control, wt emt, or kinase-dead (K390R) mutant emt-trans-
fected btk null–sBMMCs. (C) Histamine release from IgE/antigen (30 ng/ml DNP-HSA)–stimulated btk null–sBMMCs transfected with wt, K430R, xid
(R28C), SH2 (R307K), or SH3 (P265L) mutant btk cDNAs; results with wt emt– or K390R emt–transfected cells are also shown. Note that the percent-
age of histamine release from wt-sBMMCs, which had been cultured for a total of 7 wk from the start of bone marrow cell culture, is less than that ob-
served in younger cultures of BMMCs (e.g., see Fig. 2 B). In several experiments, 7-wk-old cultures of wt-sBMMCs released 10–30% of their cellular
content upon FceRI cross-linking. (D) Expression of Btk and Emt proteins in transfected xid-sBMMCs (left) and btk null–sBMMCs (center and right).
Transfected cells were lysed and analyzed by SDS-PAGE and immunoblotting with anti-BtkC (43) or anti-Emt (16) antibodies.
tution (60) exhibited somewhat higher levels of TNF-a se-
cretion than did wt btk transfectants (Fig. 5 A). Moreover,
none of the nontransfected or transfected sBMMCs se-
creted TNF-a without FceRI stimulation (data not
shown). Results similar to those shown for TNF-a secre-
tion were also obtained when we tested the effects of trans-
fection with wt versus various mutant btk cDNAs on the
ability of FceRI-stimulated xid-sBMMCs to secrete IL-2,
IL-6, and GM-CSF (data not shown).
We next investigated btk null–sBMMCs transfectants,
and in particular analyzed the domain requirements for Btk
function in FceRI-mediated cytokine production as op-
posed to degranulation. As shown in Fig. 5 B, transfection
with wt btk cDNA greatly enhanced the ability of the cells
to produce TNF-a, IL-2, IL-6, or GM-CSF in response to
FceRI-dependent activation, whereas compared with trans-
fection with vector, transfection with kinase-dead (K430R)
or SH2 mutant (R307K) btk cDNA had little or no effect.
On the other hand, relatively low levels of protein expres-
sion for the product of the SH2 mutant (R307K) were de-
tected in the stably transfected cells (Fig. 5 D, middle), indi-
cating that the potential effects of this mutant btk in this
system have not yet been adequately tested. Notably, tran-
sient transfection of btk null–sBMMCs with wt, but not ki-
nase-dead, btk also restored cytokine gene transcriptional
activities (data not shown). This finding provides further
support for the conclusion that the results reflect the role of
Btk in FceRI signaling, not any role it might have in mast
cell differentiation.
Notably, two mutant Btk proteins appeared to be able to
partially (for TNF-a, IL-2 and GM-CSF) or fully (for IL-6)
normalize 24-h cytokine production with respect to that
seen in cells that had been transfected with wt btk cDNA
(Fig. 5 B). One of these, the P265L mutation in the SH3
domain, is equivalent to the function-negative mutation in
the SH3 domain of sem-5 (61). Therefore, this result sug-
gests that at least partial FceRI-dependent cytokine secre-
tory function can be expressed in the absence of normal
Btk SH3 function.
The other mutant btk cDNA that partially restored cy-
tokine secretory ability in btk null–sBMMCs was xid (Fig.
5 B). This result may be related to the fact that levels of xid
Btk protein in btk null–sBMMCs that had been transfected
with xid btk cDNA were z20–30% greater than levels of
wt Btk protein in the corresponding wt btk transfectants (by
contrast, xid-BMMCs express only 1/5 to 1/3 the amount
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of Btk protein as do wt-BMMCs, data not shown). Thus,
in comparison to xid-BMMCs, btk null–sBMMCs that had
been transfected with xid btk cDNA greatly overexpress the
xid Btk.
We previously noted (in Fig. 2) that the defect in
FceRI-dependent degranulation and histamine release ex-
hibited by xid-BMMCs was less severe than that observed
with btk null–BMMCs. Indeed, at optimal levels of FceRI-
dependent stimulation, xid-BMMCs gave a histamine re-
lease response that was indistinguishable from that of the
corresponding wt-BMMCs (Fig. 2 A). We therefore exam-
ined the effect of transfection of btk null–sBMMCs with xid
btk and other mutant btks, as opposed to wt btk, on degran-
ulation (as assessed by histamine release) at optimal condi-
tions of IgE sensitization and antigen challenge (Fig. 5 C).
We found that the profound defect in the histamine release
response of btk null–sBMMCs under these conditions was
nearly fully restored by wt or xid btk cDNAs, was slightly
enhanced by SH2 (R307K) or SH3 (P265L) mutant btk
cDNAs, but was unaffected (relative to results obtained
with vector alone) by the kinase-dead (K430R) mutant btk
cDNA (Fig. 5 C).
Since Emt is not only closely related to Btk but is acti-
vated upon FceRI cross-linking (19), we also examined
whether Emt might influence defects in cytokine produc-
tion or degranulation in btk null–sBMMCs. We found that
btk null–sBMMCs express endogenous Emt protein (Fig. 5 D).
Moreover, the overexpression of wt Emt protein, but not
kinase-dead (K390R) Emt protein, enhanced both FceRI-
dependent cytokine production (Fig. 5 B) and histamine
release (Fig. 5 C) in btk null–sBMMCs. However, transfec-
tion of btk null–sBMMCs with wt emt did not restore either
cytokine production or histamine release to levels observed
in cells which had been transfected with wt btk (Fig. 5, B
and C).
Discussion
Btk Functions in Mast Cells and Other Hematopoietic
Cells. Btk has been shown to have essential roles in B cell
differentiation and activation. Although our in vivo and in
vitro studies have thus far revealed no significant effects of
the btk mutations on mast cell development, we have iden-
tified multiple defects in FceRI-induced activation events
in btk mutant mast cells. Both degranulation, leading to re-
lease of histamine, and production/secretion of several cy-
tokines were mildly or severely impaired, respectively.
These defects at the cellular levels probably account for the
defective expression of anaphylactic reactions in response
to IgE and antigen in btk mutant mice. Together with our
previous data demonstrating the tyrosine phosphorylation
and enzymatic activation of Btk upon FceRI cross-linking
(18), these in vivo and in vitro effects of btk mutations have
established that Btk has a role in the expression of FceRI-
dependent mast cell function.
Notably, some of the effects of btk mutations are milder
in mice than in humans. For example, X-linked agamma-
globulinemia patients have few mature B cells with no or
little immunoglobulin production, whereas xid or btk null
mice have about half the number of B cells as in normal
mice (39, 40, 62, 63). Such species differences in the conse-
quences of btk mutations raise the possibility that the effects
of btk mutations on mast cell development or function
might be milder in mice than in humans. This possibility is
currently being investigated.
The btk gene is also expressed in myeloid cells in addi-
tion to mast and B cells (16). Hence, we examined the abil-
ity of activated macrophages from btk mutant mice to se-
crete TNF-a. We found that lipopolysaccharide stimulation
induced the secretion of indistinguishably high levels of
TNF-a from wt versus xid mouse bone marrow–derived
macrophages (98% Mac-11) cultured in GM-CSF (data not
shown). Therefore, the production/secretion of TNF-a
seems to be differentially regulated in the two types of cells;
it is more dependent on Btk in mast cells than in macro-
phages. This is not surprising, given the recent data dem-
onstrating that the transcription of the TNF-a gene is reg-
ulated in a cell type–specific manner in activated T and B
cells (58).
Structural Requirements of Btk for FceRI-dependent Degranu-
lation and Cytokine Production/Secretion. Btk and Emt have,
in order from their NH2 to COOH termini, pleckstrin ho-
mology (PH), Tec homology (TH), SH3, SH2, and SH1
(5 kinase) domains. The catalytic activity of Btk was criti-
cal for mast cells to exhibit fully normal degranulation and
production/secretion in response to FceRI stimulation. In
accord with this finding, transfection of xid-sBMMCs with
a constitutively active form of Btk, Btk* with E41K muta-
tion (60), resulted in the secretion of even higher levels of
TNF-a than did transfection of the cells with wt Btk (Fig. 5
A). Interestingly, an SH3 mutant (P265L) could induce at
least partial restoration of cytokine producing/secretory ca-
pacity. Therefore, an intact SH3 domain does not appear to
be required for the expression of at least some Btk function
in this system.
Remarkably, we also found that xid (R28C mutation in
the PH domain) Btk, when overexpressed, could, depend-
ing on the cytokine, partially or apparently fully restore the
cytokine producing/secretory capacity in both xid and btk
null mast cells. The requirement of Btk domains for de-
granulation is similar to that for cytokine producing/secre-
tory capacity (Fig. 5, A–C). Interestingly, xid Btk overex-
pressors released histamine as efficiently as wt Btk transfectants
upon FceRI cross-linking with an optimal concentration of
antigen (Fig. 5 C). At first glance, these results appear in-
consistent with the finding that xid mast cells express de-
fects in FceRI-dependent function. However, xid-BMMCs
express only 1/5 to 1/3 as much Btk protein as do wt-
BMMCs. By contrast, btk null–sBMMCs that had been
transfected with xid btk cDNA expressed 20–30% more Btk
protein than did cells transfected with wt btk cDNA, and
both types of transfectant greatly overexpressed Btk protein
relative to levels in xid-BMMCs. Finally, the defects in
FceRI-dependent mast cell function in xid-BMMCs are
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less severe than those in the btk null–BMMCs; in fact, at
optimal concentrations of antigen challenge, xid-BMMCs
released histamine at levels that were indistinguishable from
those of wt-BMMCs (Fig. 2 A). Taken together with the
results obtained with the kinase-dead and SH3 mutants,
these results suggest that the kinase activity of Btk is strictly
required for Btk function in degranulation and cytokine pro-
duction and secretion, but that other domains, such as the
PH and SH3 domains, are not as essential for these func-
tions of Btk in mast cell activation.
Several Btk-associated molecules have been described.
PH domain–binding molecules include phosphatidylinosi-
tol 4,5-bisphosphate (and related phosphoinositides; refer-
ences 64–66), the b subunits of GTP-binding proteins (67,
68), PKC (43), and BAP-135 (69). A proline-rich sequence
in the Tec homology domain binds SH3 domains of Src
family PTKs (70, 71), whereas the SH3 domain of Btk in-
teracts with a protooncogene product, p120c-cbl (72). Differ-
ential binding requirements of some of PH domain–associated
signaling molecules may account for the observed differ-
ences in the biochemical capacities or biological functions
of xid versus wt Btk.
We found that wt, but not kinase-dead (K390R), Emt
could partially compensate for the absence of Btk in the ex-
pression of FceRI-dependent mast cell degranulation and
cytokine production/secretion. Emt protein levels in wt
and btk null mast cells, as revealed by immunoblotting with
an anti-Emt polyclonal antibody that cross-reacts with Btk,
were estimated to be z10% of the Btk level in wt mast cells
(Fig. 5 D), assuming that the antibody binds to Emt and
Btk with the same efficiency. Given this finding and the re-
sults of our emt transfection experiments, it is possible that
the retention of limited degranulation and cytokine pro-
duction capacity in xid or btk null mutant mast cells may re-
flect low-level expression of Emt (and/or other Tec family
PTKs) in these cells. This possibility remains to be investi-
gated using mast cells devoid of both Btk and Emt (and/or
other Tec family) proteins.
Btk Regulates the Transcription of Several Cytokine Genes.
The abnormalities in the production/secretion of cytokines
in btk mutant mast cells seem to be at the transcriptional
level. Thus, levels of TNF-a mRNA induced by FceRI
cross-linking in wt mast cells exceeded that in xid mast cells
by at least fivefold. This difference in mRNA levels could
be due to differences in the transcription rate and/or in the
mRNA stability, both phenomena known for IL-2 and
other cytokines (73). In addition, the TNF-a mRNA has
AU-rich sequences at the 39 untranslated region that pre-
dispose for mRNA degradation and repress its translation
(74–76). Although the possibilities of differential cytokine
mRNA stabilities and differential derepression of mRNA
translation between wt and btk mutant mast cells are not
ruled out by this study, the notion of Btk-mediated regula-
tion of cytokine gene transcriptions can account largely for
our data. Thus, promoter reporter assays using the con-
structs without the 39 AU-rich sequences demonstrated
significant differences between wt and btk mutant mast cells
in the transcriptional activity of the TNF-a and IL-2 pro-
moters and individual cis-elements (see below) upon FceRI
cross-linking. By contrast, we found that the xid mutation
had little or no detectable effect on the posttranslational
regulation of TNF-a expression. All of these data are con-
sistent with the fact that the expression of this cytokine is
regulated at the transcriptional level by the activation of
critical transcription factors in activated T and B cells (56–
58, 77).
Similar observations were made with promoter reporter
constructs to examine individual cis-acting elements. Thus,
NFAT activity was activated by FceRI stimulation, as pre-
viously shown in a mast cell line, CPII (78). However, FceRI-
induced transcriptional activation of an NFAT–luciferase
construct was lower in btk null cells than in wt cells. In con-
trast, NFkB–luciferase and c-fos–luciferase activities were
induced (at relatively low levels) by FceRI stimulation, but
the extent of transcriptional activation of these constructs
was similar in wt versus btk null mast cells (data not shown).
These observations are consistent with the results obtained
with btk null mast cells that had been transfected with vec-
tor, wt btk, or kinase-dead btk cDNAs (Fig. 4 B). NFATp
binds to four sites in the TNF-a promoter (58). Together
with NFAT, the CRE site just upstream of k3, an
NFATp-binding site, binds c-Jun and ATF-2 transcription
factors to activate this gene in response to TCR/CD3
stimulation (57, 58). NFATp binds to five sites in the IL-2
gene promoter (55) and cooperatively binds with c-Fos–
c-Jun heterodimers or c-Jun–c-Jun homodimers at these
sites (55, 79). Thus, it is likely that the regulation of the
TNF-a and IL-2 genes in mast cells also involves NFAT
and AP-1 proteins.
Btk-dependent Signaling Pathways. Btk is activated by
the phosphorylation of tyrosine-551 by Lyn (80). Activated
Btk in turn autophosphorylates Tyr-223 in the SH3 do-
main (81). Chicken DT-40 B lymphoma cells in which the
btk gene was knocked out exhibited reduced tyrosine phos-
phorylation of PLC-g2 and little [Ca21]i rise in response to
anti-IgM stimulation, suggesting a role of Btk in the regu-
lation of intracellular Ca21 concentrations through direct or
indirect phosphorylation of PLC-g2 (82). Reaction prod-
ucts of PLC, inositol 1,4,5-trisphosphate, and diacylglyc-
erol, mobilize Ca21 from intracellular storage sites and acti-
vate PKC, respectively (for review see reference 83).
Increased Ca21 concentrations also lead to the activation
and nuclear translocation of NFAT by dephosphorylation
of cytoplasmic NFAT by the calcium/calmodulin–depen-
dent phosphatase, calcineurin (for review see reference 84).
Our recent data indicates that Btk regulates JNKs and, to
a lesser extent, p38, representing two of the three major
MAP kinases (i.e., ERKs, JNKs, and p38) that are activated
upon FceRI cross-linking (59). Thus, upon FceRI cross-
linking, xid and btk null mast cells exhibited much reduced
JNK activation compared with wt mast cells. Notably, the
activities of ERKs upon FceRI cross-linking were not sig-
nificantly different between wt and btk mutant mast cells.
The activity of phospholipase A2, a key enzyme of arachi-
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donic acid cascade, was shown to be regulated by ERK,
which in turn is regulated by Syk in rat basophilic leukemia
RBL-2H3 cells (85). Accordingly, the lack of effect of btk
mutations on ERK activity after FceRI cross-linking prob-
ably explains our finding that leukotriene levels released
from btk null mast cells were similar to those from wt mast
cells (data not shown). Similarly, we found that the tran-
scriptional activity of a c-fos–luciferase construct was not
affected by btk mutations in mast cells (c-fos is also down-
stream of ERK).
btk mutations would be expected to impair signaling
through JNKs (59). Targets of JNK include the transcrip-
tion factors c-Jun and ATF-2. JNK phosphorylates the crit-
ical residues of the activation domains of these proteins to
activate them (86–88). c-Jun and ATF-2, in cooperation
with NFAT, were shown to bind to the CRE and k3 sites,
respectively, which are required for the induction of the
TNF-a promoter (57, 58). In the case of the IL-2 gene,
Fos–Jun heterodimers cooperatively bind with NFAT pro-
teins at four of the five NFAT-binding sites in the IL-2
promoter (55). Taken together with these previous find-
ings, our current data are consistent with the hypothesis
that Btk can regulate two arms of the FceRI signaling pro-
cess, i.e., the PLC/Ca21/PKC and JNK signaling pathways
(Fig. 6).
On the other hand, the regulation of FceRI signaling is
potentially very complex, and not all of these complexities
are illustrated in Fig. 6. For example, we found that the se-
cretion of TNF-a and other cytokines upon FceRI cross-
linking was greater in mast cells that had been cultured in
the presence of both IL-3 and SCF as compared with that
in cells that had been cultured in IL-3 alone. This might
reflect, at least in part, the phosphorylation and enzymatic
activation of PLC-g by c-Kit (89, 90), the receptor for
SCF. JNK is also activated transiently by SCF stimulation
of BMMCs (59). Therefore, SCF/c-Kit–dependent activa-
tion of both PLC/Ca21/PKC and JNK pathways probably
contributed to cytokine gene induction in mast cells that
were maintained in IL-3 and SCF.
Figure 6. Hypothetical scheme of the roles of Btk in FceRI-mediated
signal transduction. Phosphorylation at Tyr-551 by activated Lyn leads to
activation of Btk. Activated Btk in turn may phosphorylate PLC-g, lead-
ing to Ca21 mobilization. This pathway will activate NFAT as a result of
dephosphorylation by calcineurin. Btk also can activate the JNK/SAPK
pathway, resulting in the activation of c-Jun and ATF-2 by the phosphor-
ylation of critical residues. Active NFAT, c-Jun and ATF-2 then lead to
the transcriptional activation of cytokine genes.
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